Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Can Respir J ; 2021: 5644824, 2021.
Article in English | MEDLINE | ID: mdl-34824650

ABSTRACT

Background: Pneumonia is a common disease among the aging population in Japan. Hence, it is important to elucidate the risks related to pneumonia mortality. Since Streptococcus pneumoniae is the most commonly observed pathogen, pneumococcal vaccination is recommended to older adults. Therefore, this study aimed to clarify the clinical features of pneumonia, including the status of pneumococcal vaccination, in hospitalized older adult patients in Japan. Methods: This single-centered retrospective study was conducted by reviewing the medical records of all patients with acute pneumonia at Fujisawa City Hospital in Japan from April 2018 to March 2019. Patients were divided into two groups based on their history of pneumococcal vaccination. The primary endpoint was in-hospital mortality, while the secondary endpoint was risk factors associated with mortality. Results: We included 93 patients with pneumonia in this retrospective study. Although the mortality rate was higher in the vaccinated group (15.8%) than in the unvaccinated group (9.1%), vaccination status was not identified as a significant risk factor for mortality after multivariable logistic regression (odds ratio: 2.71; 95% confidence interval: 0.667-11.02; p=0.16). In addition, the A-DROP score was identified as an independent risk factor (odds ratio: 2.64; 95% confidence interval: 1.22-5.72; p=0.008). Conclusions: Our study suggested that the A-DROP score is a risk factor of mortality for pneumonia in older adults. In addition, pneumococcal vaccination history was related to increased mortality; however, the influence of the vaccination remains unclear because of the small sample size.


Subject(s)
Pneumococcal Infections , Pneumonia, Pneumococcal , Pneumonia , Aged , Humans , Retrospective Studies , Risk Factors , Streptococcus pneumoniae
2.
Case Rep Oncol Med ; 2019: 2759650, 2019.
Article in English | MEDLINE | ID: mdl-31316848

ABSTRACT

Malignant phyllodes tumors of the breast occur infrequently and are difficult to treat with chemotherapy. Here, we present an effective chemotherapy strategy for recurrent malignant breast phyllodes tumors. A 48-year-old woman was diagnosed with a malignant phyllodes tumor in her right breast and underwent total right mastectomy. One year later, the tumor recurred in the right (a 2.2 cm mass) and left (a 10 cm mass) lungs; pleural effusion was also observed in the left lung. Eight courses of doxorubicin-ifosfamide (AI) therapy were administered. After treatment, the right lung mass and pleural effusion regressed completely and the left lung mass regressed to 2 cm. In conclusion, AI therapy is useful for treating recurrent malignant breast phyllodes tumors.

4.
Intern Med ; 51(22): 3115-8, 2012.
Article in English | MEDLINE | ID: mdl-23154715

ABSTRACT

OBJECTIVE: The aim of this study was to determine the epidemiological characteristics of never-smoking patients with non-small cell lung cancer (NSCLC) detected with clinic-based screening programs, focusing on clinical risk factors and survival. METHODS: The medical records of NSCLC patients (n=285) diagnosed at Fujisawa City Hospital between April 2000 and December 2010 with lesions that were originally detected with clinic-based screening programs in Fujisawa City were reviewed to identify the clinicopathological variables and survival outcomes. RESULTS: Of the 285 NSCLC patients, 95 (33.3%) were never-smokers. A comparison between the never-smoking and ever-smoking patients revealed that the never-smokers included a significantly greater proportion of women and patients with adenocarcinoma (86.3% vs. 12.6%: p<0.001 or 94.7% vs. 55.8%: p<0.001, respectively). The overall survival rate of the never-smoking patients was significantly superior to that of the ever-smokers (p=0.004). In addition to smoking status, factors found to be significantly associated with the overall survival rate in univariate analyses were gender, stage, histology and first line treatment. A multivariate analysis revealed smoking status to be an independent prognostic factor in addition to stage and first line treatment. CONCLUSION: The differences in the clinicopathological factors and survival outcomes between never-smoking and ever-smoking patients with NSCLC detected with clinic-based screening programs suggest that persuading people to never start smoking is important.


Subject(s)
Carcinoma, Non-Small-Cell Lung/mortality , Lung Neoplasms/mortality , Smoking , Adenocarcinoma/mortality , Aged , Female , Humans , Japan/epidemiology , Kaplan-Meier Estimate , Male , Mass Screening , Middle Aged , Prognosis , Sex Characteristics , Smoking/adverse effects , Smoking/epidemiology
5.
Nihon Kokyuki Gakkai Zasshi ; 48(11): 825-30, 2010 Nov.
Article in Japanese | MEDLINE | ID: mdl-21141061

ABSTRACT

A 70-year-old man visited hospital because of intermittent fever (about 38 degrees C) and night sweat. He had a history of smoking of 1 pack a day for 35 years. He had no abnormal findings on physical examination, but had abnormal laboratory findings, including elevated C-reactive protein, lactate dehydrogenase and soluble interleukin-2 receptor levels. Although malignant lymphoma was suspected, his symptoms and laboratory findings resolved spontaneously. However, intermittent fever and night sweat reoccurred 19 months after his first presentation, and he visited our hospital with dyspnea the following month. On physical examination, he had no abnormal findings. A chest radiograph showed no abnormal findings, but chest and abdominal CT images revealed diffuse ground-glass opacities in both lung fields, and splenomegaly. Transbronchial lung biopsy (TBLB) confirmed a diagnosis of intravascular large B-cell lymphoma. Spontaneous remission is rare in aggressive lymphomas, including intravascular lymphomas (IVL). We report a case of IVL, with symptoms which resolved spontaneously, and reoccurred 19 months later with diffuse interstitial shadows on chest CT images, and in which a diagnosis of IVL was confirmed by TBLB.


Subject(s)
Biopsy/methods , Lung/pathology , Lymphoma, Large B-Cell, Diffuse/diagnosis , Remission, Spontaneous , Vascular Neoplasms/diagnosis , Aged , Diagnosis, Differential , Humans , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Neoplasm Recurrence, Local , Vascular Neoplasms/pathology
6.
Nihon Kokyuki Gakkai Zasshi ; 46(3): 248-52, 2008 Mar.
Article in Japanese | MEDLINE | ID: mdl-18409575

ABSTRACT

A 76-year-old woman with chronic tuberculous empyema presented with bloody sputa and anorexia in April 2005. Chest X-ray and CT scan showed no obvious change compared with previous films. She complained of a left chest pain in June 2005, and chest CT scan showed a tumor shadow enhanced heterogeneously on the left chest wall and chronic empyema. After admission, the chest wall mass grew rapidly. Neither CT- nor sonographically guided biopsy yielded a definitive diagnosis. Dynamic MRI showed a high signal intensity unlike hematoma. She died of respiratory failure 2 months after the onset of her chest pain. Autopsy revealed angiosarcoma. We should always keep in mind the early diagnosis of malignant tumor and tuberculosis in patients presenting with a chest wall mass and constitutional symptoms during follow-up of chronic tuberculous empyema.


Subject(s)
Empyema, Tuberculous/complications , Hemangiosarcoma/diagnosis , Thoracic Neoplasms/diagnosis , Aged , Autopsy , Female , Hemangiosarcoma/complications , Humans , Thoracic Neoplasms/complications
7.
Gan To Kagaku Ryoho ; 33(10): 1437-40, 2006 Oct.
Article in Japanese | MEDLINE | ID: mdl-17033233

ABSTRACT

The purpose of this study was to evaluate the survival outcome in patients with advanced and previously treated non-small cell lung cancer given gefitinib (GEF) at our institution. We reviewed the clinical records of 70 Japanese patients,among whom 33 received several chemotherapy treatment modalities including GEF monotherapy (GEF group), and the other 37 were given several chemotherapy treatment modalities without GEF monotherapy (non-GEF group). The median survival time (MST) after second-line chemotherapy in the GEF group was 527 days with 1-year and 2-year survival rates of 59% and 26%, respectively. The MST in the non-GEF group was 175 days with 1-year and 2-year survival rates of 21% and 16%, respectively. Overall survival after second-line chemotherapy in the GEF group was significantly longer than in the non-GEF group (hazard ratio 1.93; 95% confidence interval 1.15-3.53, p=0.014). In our limited clinical experience, chemotherapy treatment including GEF monotherapy appeared to have longer survival than non-GEF treatment.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Quinazolines/therapeutic use , Aged , Carcinoma, Non-Small-Cell Lung/mortality , Drug Administration Schedule , ErbB Receptors/antagonists & inhibitors , Female , Gefitinib , Humans , Lung Neoplasms/mortality , Male , Middle Aged , Survival Rate
8.
Nihon Kokyuki Gakkai Zasshi ; 41(8): 546-50, 2003 Aug.
Article in Japanese | MEDLINE | ID: mdl-14503341

ABSTRACT

We report a case of lung infection due to Mycobacterium abscessus (M. abscessus). A 60 year-old woman was admitted to our hospital because of an abnormal shadow found on chest radiography and a bloody sputum. Chest radiography revealed infiltrative and linear shadows in the middle and lower fields of both lungs. The sputum smears were negative for acid-fast bacilli, but sputum culture was positive. Rapidly growing mycobacteria were detected. The patient was treated with clarithromycin. Since M. abscessus was identified from repeated cultures of the sputa, the patient was treated with Imipenem/Cilastatin and Amikacin for four weeks, during which the chest radiography improved. After discharge, the treatment with clarithromycin and minocycline was continued for ten months, and the chest radiography improved further. Our treatment for M. abscessus may be a useful choice for drug treatment of such cases.


Subject(s)
Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium chelonae/isolation & purification , Tuberculosis, Pulmonary/microbiology , Amikacin/therapeutic use , Cilastatin/therapeutic use , Cilastatin, Imipenem Drug Combination , Clarithromycin/therapeutic use , Drug Combinations , Drug Therapy, Combination/therapeutic use , Female , Humans , Imipenem/therapeutic use , Middle Aged , Minocycline/therapeutic use , Mycobacterium Infections, Nontuberculous/diagnostic imaging , Mycobacterium Infections, Nontuberculous/drug therapy , Radiography , Sputum/microbiology , Tuberculosis, Pulmonary/diagnostic imaging , Tuberculosis, Pulmonary/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...